Eptifibatide and ST Segment Resolution Following Primary PCI

Exclusion Criteria

• •Patients with cardiogenic shock (SBP\<80 mmHg for \>30 minutes or requiring pressors or IABP due to hypotension)
• •Patients with cardiac arrest at any point prior to intervention (within the preceeding 24 hours)
• •Patients on chronic warfarin (Coumadin) therapy
• •Patients with known bleeding diathesis or active bleeding at the time of presentation to the catheterization laboratory
• •Patients with known bleeding diathesis or active bleeding within prior 3 months
• •Patients who receive thrombolytic therapy or glycoprotein IIb/IIIa inhibitors prior to PCI (within the preceding 8 hours)
• •Patients with a platelet count \<100,000 cells/mm3 within the preceeding 7 days
• •Patients with known allergies to aspirin, clopidogrel bisulfate (Plavix), heparin, bivalirudin, glycoprotein IIb/IIIa inhibitors or intravenous contrast dye that cannot be medically managed
• •Patients with major surgery within the past 6 months or scheduled surgery within 6 weeks
• •Patients with significant unprotected left main disease (stenosis \>60%) or with multivessel coronary disease that will require emergent coronary artery bypass surgery
• •Patients with TIA or CVA within the past 30 days or any history of hemorrhagic stroke
• •Patients who have undergone PCI within the preceding 30 days prior to enrollment
• •Patients with known impaired renal function
• •Patient is know to be pregnant or lactating
• •Patients with active participation in another device or drug study
• •Patients with comorbidities conferring a life expectancy of less than a year
• •Patients with left bundle branch block